Fundz

ChronoScale Holdings Corp

Menlo Park, California, United States · Artificial Intelligence, Biotechnology, Health Care

® Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only k

Key facts

Headquarters
Menlo Park, California, United States
Employees
Unknown
Industries
Artificial Intelligence, Biotechnology, Health Care
Status
Public (CHRN)
Website
chronoscale.com

Recent activity at ChronoScale Holdings Corp

  • : ChronoScale Holdings Corporation Secures $153 Million in Funding
  • : ChronoScale partners with Microsoft to enhance AI infrastructure capabilities. (date Fundz recorded it)
  • : ChronoScale Holdings Appoints Jerome Wong as Chief Financial Officer
  • : SEC 8-K (8.01): The filing discusses significant developments related to a Common Stock Private Placement, where the Company presented its Investor Presentation to potential investors. The attached Exhibit 99.2 contains the Investor Presentation dated November 18, 2026, which likely outlines key financial information, strategic initiatives, and potential investment opportunities. This event occurred recently, on the same date as the filing, indicating an active engagement with investors to secure funding. The information shared could influence investor decisions and the company's capital structure.
  • : SEC 8-K (1.01): On November 18, 2026, ChronoScale Holdings Corporation entered into definitive agreements for two concurrent private placements: a Common Stock Purchase Agreement and a Preferred Equity Purchase Agreement, together valued at up to $500,000,000. The Company expects to close on the Common Stock Purchase Agreement, raising $153.0 million through the sale of approximately 19.1 million shares of common stock at $8.00 per share. The proceeds will fund a partnership commitment for a data center project in Odessa, Texas, including GPU purchases and general corporate purposes. Additionally, a put notice for $10.0 million of Series C Preferred Stock shares is also planned for the same date, marking a significant financial transaction for the company.
  • : SEC 8-K (5.02): Scott Davis, the Chief Executive Officer of Ekso Bionics, Inc. and a member of ChronoScale Holdings Corporation's Board of Directors, resigned from his position effective October 3, 2026, in connection with the company's recent sale of Ekso Bionics on September 30, 2026. As part of the transaction, Mr. Davis received an award of 51,626 restricted stock units that vested immediately and a lump sum cash payment of $709,500 under a Release Agreement. This payment is contingent upon his compliance with the agreement and his continuing restrictive covenants, and it satisfies any prior severance entitlements he had. There were no disagreements leading to his resignation, highlighting a smooth transition related to the sale.
  • : SEC 8-K (5.02): On September 30, 2026, ChronoScale Holdings Corporation finalized the sale of their wholly owned subsidiary, Ekso Bionics, Inc. In conjunction with this transaction, Jason C. Jones, who was the Chief Operating Officer of Ekso, was terminated from his position effective on the same day, September 30, 2026. Ekso has entered into a Separation and Severance Agreement with Mr. Jones as part of this transition. The implications of this event could impact company operations and management structure, highlighting strategic shifts within ChronoScale as they streamline their holdings.
  • : SEC 8-K (1.01):
  • : SEC 8-K (7.01): On August 27, 2026, ChronoScale Holdings Corporation announced a strategic partnership with Microsoft Corporation aimed at deploying a 50-megawatt AI compute system. This partnership highlights the commitment of both companies to enhance their technological capabilities and strategic market positioning. The deployment is expected to leverage Microsoft’s cloud infrastructure to improve AI performance and operational efficiency. Further details regarding the terms of this partnership and its expected impact on ChronoScale’s business strategy were released in the related press release, which is included as Exhibit 99.1.
  • : SEC 8-K (5.02): On August 16, 2026, ChronoScale Corporation, a wholly-owned subsidiary of ChronoScale Holdings Corporation, entered into an Offer of Continued Employment with Jerome Wong, the Chief Financial Officer. The agreement includes an Employee Non-Disclosure, Invention Assignment, and Restrictive Covenants Agreement. This arrangement confirms Mr. Wong's position with the company, thereby providing continuity in its financial leadership. The strategic implications likely include stability in financial management as the company navigates its operations in a dynamic market environment.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

ChronoScale Holdings Corp funding history

DateRoundAmount
Nov 2026Series C$153.0M

Leadership

  • Alma Mercado, Human Resources Director
  • Jerome Wong, Chief Financial Officer
  • Raj Jegannathan, Chief Technology Officer
  • Lawrence Lam, Chief Product Officer

Verified email and direct lines for ChronoScale Holdings Corp’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

ChronoScale Holdings Corp files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

ChronoScale Holdings Corp in the news

Companies similar to ChronoScale Holdings Corp

  • Scarlet · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Manufacturing, Medical Device, Software
  • Corologic · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Manufacturing, Medical Device
  • AIBORN Ltd · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Medical Device, Software
  • FotoFinder Systems · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Manufacturing, Medical Device
  • Quality Means Business (QMB) · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Medical Device, Software

About ChronoScale Holdings Corp: questions and answers

What does ChronoScale Holdings Corp do?

® Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only k

Where is ChronoScale Holdings Corp headquartered?

ChronoScale Holdings Corp is headquartered in Menlo Park, California, United States.

Has ChronoScale Holdings Corp raised funding?

Yes. Fundz has recorded 1 funding event for ChronoScale Holdings Corp. The most recent, Series C of $153.0M, was in Nov 2026.

What is the latest news on ChronoScale Holdings Corp?

On Nov 18, 2026, ChronoScale Holdings Corporation Secures $153 Million in Funding

Is ChronoScale Holdings Corp a public company?

Yes. ChronoScale Holdings Corp is publicly traded under the ticker CHRN.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches ChronoScale Holdings Corp across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.